Integrated strategies of network pharmacology, transcriptomics, and computational and experimental validation reveal the anti-osteosarcoma effects of juglone via the ROS/PI3K/AKT pathway
European Journal of Pharmacology · 2026-01 · 1011 · 178462
DOI: 10.1016/j.ejphar.2025.178462 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026-01. Verfasst von Haichuan Miao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dalian Medical University, Dalian, 116044, China. Hauptthemen laut MEDLINE: Naphthoquinones, Osteosarcoma, Proto-Oncogene Proteins c-akt, Reactive Oxygen Species. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Liaoning Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: Osteosarcoma (OS), the most common primary malignant bone tumor, exhibits poor prognosis, underscoring the need for new therapies. Juglone, a natural naphthoquinone, shows therapeutic promise; however, the effects of juglone on OS and underlying mechanisms remain to be elucidated. MATERIALS AND METHODS: In vitro experiments were validated using U2OS and HOS cell lines. Network pharmacology predicted juglone-OS targets, followed by protein-protein interaction (PPI) network construction and GO/KEGG enrichment analysis. Transcriptomics analysis was further confirmed. Molecular docking was performed using AutoDock Tools and Discovery Studio. Molecular dynamics simulations (MD) using GROMACS confirmed the stability of the juglone-target complex. In vivo experiments clarified the effect of juglone in vivo. ADME/T was profiled using Swiss and Protox. RESULTS: Juglone inhibited OS cell viability, promoted apoptosis, suppressed proliferation and migration, and induced G2/M arrest. A total of 234 targets were identified; PPI highlighted key interactors (TP53, AKT1, BCL2, CTNNB1, STAT3). Enrichment analyses revealed associations with oxidative stress and PI3K/AKT pathways. Molecular docking showed high-affinity binding to PI3K and AKT1, confirmed stable by molecular dynamics. Mechanistically, juglone inhibits OS via the ROS/PI3K/AKT pathway. In vivo, it potently inhibited tumor growth in xenograft models with short-term biosafety. ADME/T profiling indicated favorable pharmacokinetics but potential toxicity risks. CONCLUSION: This study first demonstrates juglone's anti-OS efficacy via the ROS/PI3K/AKT pathway. In vivo studies confirm potent tumor suppression with short-term safety, supporting its clinical promise for OS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dalian Medical University, Dalian, 116044, China.
- Department of Developmental Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, China Medical University, 77 Puhe Road, Shenbei New District, 110122, Shenyang, China.
- Department of Laboratory Medicine, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116044, China.
- Department of Orthopaedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, China.
- Department of Sports Medicine and Joint Surgery, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang, 110016, China. Electronic address: yzs5269@126.com.
- Orthopedic Department, Taizhou Hospital of Zhejiang Province, School of Medicine, Zhejiang University, Taizhou, 317000, China. Electronic address: medzlw@sina.com.
Förderung
- Liaoning Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Miao, H., Liu, B., Pan, X., Cheng, Z., Xue, Q., Han, D., Yu, Z., Zhang, L., & Bai, X. (2026). Integrated strategies of network pharmacology, transcriptomics, and computational and experimental validation reveal the anti-osteosarcoma effects of juglone via the ROS/PI3K/AKT pathway. European Journal of Pharmacology, 1011, 178462. https://doi.org/10.1016/j.ejphar.2025.178462
Vancouver
Miao H, Liu B, Pan X, Cheng Z, Xue Q, Han D, et al. Integrated strategies of network pharmacology, transcriptomics, and computational and experimental validation reveal the anti-osteosarcoma effects of juglone via the ROS/PI3K/AKT pathway. European Journal of Pharmacology. 2026;1011:178462. doi:10.1016/j.ejphar.2025.178462
BibTeX
@article{Miao2026,
author = {Miao, Haichuan and Liu, Baolong and Pan, Xinfang and Cheng, Zhihua and Xue, Qizhen and Han, Dongda and Yu, Zhongshen and Zhang, Liwei and Bai, Xizhuang},
title = {Integrated strategies of network pharmacology, transcriptomics, and computational and experimental validation reveal the anti-osteosarcoma effects of juglone via the ROS/PI3K/AKT pathway},
journal = {European Journal of Pharmacology},
year = {2026},
volume = {1011},
pages = {178462},
doi = {10.1016/j.ejphar.2025.178462}
}
EUVIMED